F Vanaclocha

Publications (43)48.9 Total impact

• Article: Electrosurgery in Patients With Implantable Electronic Cardiac Devices (Pacemakers and Defibrillators).

  B García Bracamonte, J Rodriguez, R Casado, F Vanaclocha
  [show abstract] [hide abstract]
  ABSTRACT: The electrosurgical unit is a very useful tool widely used in dermatology to treat benign and malignant skin lesions and to achieve hemostasis during surgery. However, precautions are required when this technique is used in patients with implantable electronic cardiac devices (IECD), such as pacemakers and defibrillators, because electromagnetic interference produced by the tool may cause such devices to malfunction. Before using electrosurgery in patients with IECDs, it is essential to ascertain the type of implanted device and the patient's level of dependence on it. The location of the skin lesion to be treated with respect to the device should also be assessed. Bipolar pacemakers are more resistant to interference. Appropriate monitoring and the use of bipolar forceps are recommended.
  Actas Dermo-Sifiliográficas 12/2012;
• Article: Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain.BIOBADADERM registry.

  A I Sánchez-Moya, I García-Doval, G Carretero, J Sánchez-Carazo, C Ferrandiz, E Herrera Ceballos, M Alsina, M Ferrán, J-L López-Estebaranz, F Gómez-García, P De la Cueva Dobao, J-M Carrascosa, F Vanaclocha, I Belinchón, F Peral, E Dauden
  [show abstract] [hide abstract]
  ABSTRACT: Introduction  The incidence of tuberculosis (TB) or the prevalence of latent tuberculosis infection (LTBI) in psoriasis patients has not been described in the Spanish population. We carried out a study with the objectives: (i) To describe the incidence of TB in patients with psoriasis on systemic treatment in the Spanish population; (ii) To determine the prevalence of LTBI in patients who are candidates for biological treatment; and (iii) To investigate the level of compliance with current recommendations for LTBI and TB screening. Methods  Data were obtained from BIOBADADERM (Spanish registry for systemic biological and non-biological treatments in psoriasis). An analysis was performed of the exposed cohort to determine the prevalence of LTBI and to describe compliance with the screening guidelines. Results  A total of 1425 patients were registered in BIOBADADERM. They included 793 (56%) patients exposed to biological treatment and 632 (44%) treated with conventional systemic drug. Overall follow-up was 3720 person-years. Of the 793, 20.5% (163) were diagnosed with LTBI before starting biological treatment. The rate of active TB for the exposed cohort was 145 cases × 100 000 patient-years (95% CI 54-389). No case of TB was found in the control group. Screening for LTBI was performed in 83% of the exposed sample. Conclusion  Patients with psoriasis who are exposed to biological treatment appear to be at greater risk for tuberculosis. In Spain, up to 20% of patients with psoriasis who are candidates for biological therapy have LTBI. There continues to be a significant percentage of errors in compliance with clinical guidelines.
  Journal of the European Academy of Dermatology and Venereology 11/2012; · 2.98 Impact Factor
• Article: Deep Vein Thrombosis in a Patient With Lepromatous Leprosy Receiving Thalidomide to Treat Leprosy Reaction.

  G Hebe Petiti-Martin, M Villar-Buill, I de la Hera, L Fuertes, M Burgués-Calderón, R Rivera-Díaz, F Vanaclocha
  [show abstract] [hide abstract]
  ABSTRACT: Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
  Actas Dermo-Sifiliográficas 06/2012;
• Article: Anogenital granulomatosis.

  M Villar, G Petiti, A Guerra, F Vanaclocha
  Actas Dermo-Sifiliográficas 01/2012; 103(1):76-9.
• Article: [Localized primary cutaneous nodular amyloidosis in a patient with paraproteinemia].

  M Villar, M Burgués, J L Rodríguez-Peralto, R Rivera, F Vanaclocha
  Actas Dermo-Sifiliográficas 08/2011; 103(2):161-2.
• Article: Necrosis of ears after use of cocaine probably adulterated with levamisole.

  I de la Hera, V Sanz, D Cullen, R Chico, G Petiti, M Villar, M Burgués, J Sanz, M Castellanos, O Zarco, P L Ortiz, J L Rodríguez-Peralto, F Vanaclocha
  [show abstract] [hide abstract]
  ABSTRACT: Levamisole is an anthelminthic drug with immunomodulatory properties that has been found to be an adulterant of cocaine in the last 2 years. It was present at least in 70% of tainted cocaine in the U.S.A. in 2009. We present the case of a 40-year-old patient with a history of weekend cocaine use who consulted for bilateral necrotic lesions in the ears that had appeared 3 days after the last use. Levamisole causes a typical clinical picture characterized by bilateral necrosis of the ears, positive perinuclear antineutrophil cytoplasmic antibodies and laboratory findings of antiphospholipid syndrome, such as anticardiolipin antibodies and/or lupus anticoagulant. Dermatologists should be aware of this new entity, which is likely to be more and more frequent due to the increasing use of cocaine. Here we describe a clinical case that is likely to be secondary to levamisole-tainted cocaine and review the literature.
  Dermatology 08/2011; 223(1):25-8. · 2.05 Impact Factor
• Source

  Available from: Ignacio García-Doval

  Article: [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].

  R Rivera, I García-Doval, G Carretero, E Daudén, J Sánchez-Carazo, C Ferrándiz, E Herrera, M Alsina, M Ferrán, J L López-Estebaranz, F Gómez, J M Herranz, J M Carrascosa, F Vanaclocha
  [show abstract] [hide abstract]
  ABSTRACT: The Working Group on Psoriasis of the Spanish Academy of Dermatology and Venereology has initiated BIOBADADERM, a registry of patients with psoriasis receiving treatment with biologic drugs, in order to assess the long-term risk of adverse events (AEs). A multicenter study was undertaken in 2 cohorts of patients with psoriasis: patients receiving biologic therapy and patients receiving nonbiologic systemic therapy other than phototherapy. Similar numbers of patients were included in each group. Information was recorded on demographic and clinical variables, treatment, and relevant AEs. The risk of specific AEs was determined by comparison of the frequencies for those events in the 2 cohorts. Data on the 2 cohorts were evaluated for the period from October, 2008 to November, 2009 alongside retrospective data on patients treated with biologics since 2005. Thirteen Spanish hospitals participated in the study. A total of 632 patients were included in the analysis: 417 treated with biologic drugs and 215 controls. Suspension of biologic therapy due to AEs was rare (72 cycles, 10%). A total of 232 AEs were reported in patients receiving biologic therapy. The majority were not serious. The most frequent AEs were infections (mostly upper respiratory tract infections and nasopharyngitis), followed by conditions affecting the skin or subcutaneous tissue. Forty-three AEs were reported in control subjects. The most frequent events were metabolic and nutritional abnormalities and abnormal transaminase levels. Comparison of the incidence of any AE in patients treated with biologics compared with control subjects revealed a relative risk of 2.2 (P<.001) The relative risks of infections or infestations and disorders of the skin or subcutaneous tissue in patients receiving biologic drugs were 23 (P<.01) and 4.9 (P<.05), respectively. Patients treated with biologic drugs had a greater number of AEs, particularly infections and skin conditions. Definitive conclusions, however, are difficult to draw due to the small number of patients included in the registry, particularly in the control cohort, and the short follow-up period. Differences in the percentages of events reported by the different hospitals reveal the difficulties associated with the concept of AEs in clinical practice and highlight the need to harmonize criteria in the future. Since the problems identified in this analysis should be overcome in future years, we expect BIOBADADERM to become an important source of information on the safety profile of biologic drugs in dermatology.
  Actas Dermo-Sifiliográficas 03/2011; 102(2):132-41.
• Article: [Sensitization to methylchloroisothiazolinone-methylisothiazolinone after a burn caused by massive accidental occupational exposure].

  V Monsálvez, L Fuertes, J Ortiz de Frutos, F Vanaclocha
  Actas Dermo-Sifiliográficas 01/2011; 102(3):224-6.
• Article: [Linear Darier disease].

  I de la Hera, R Chico, R Llamas, F Vanaclocha
  Actas Dermo-Sifiliográficas 01/2011; 102(4):299-301.
• Article: [Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study].

  M Ribera, E Daudén, L Puig, V García-Patos Briones, J M Herranz, X Bordas, F Vanaclocha
  [show abstract] [hide abstract]
  ABSTRACT: the aim of this study was to design and assess the validity, reliability, and sensitivity to change of the Spanish Satisfaction With Treatment of Psoriasis Questionnaire (SSTPQ) for use in patients with moderate-to-severe psoriasis. a prospective, multicenter, observational, naturalistic study was designed. The instrument consisted of 12 items scored on a 5-point Likert scale with scores from 0 (very satisfied) to 5 (very unsatisfied), generating a total score of 0 to 48. Patients completed the questionnaire at baseline and then at 3-, 6-, 9-, and 12-month follow-up. At each visit, data were also collected on the Psoriasis Area and Severity Index (PASI), treatment adherence (Morisky-Green questionnaire), and overall treatment satisfaction on a Visual Analogue Scale (VAS) from 0 to 100. a total of 423 patients were included in the study and 68% completed 12 months of follow-up. Responses were provided to all items in 98.8% of cases. There was a weak correlation between changes in treatment satisfaction on the SSTPQ and changes in PASI score (r = 0.38 to 0.33); in contrast, there were strong correlations with changes in the VAS score for overall treatment satisfaction (r = -0.75 to -0.81). Good internal consistency was observed (Cronbach α = 0.92). The intraclass correlation coefficient was 0.89, with a mean difference in score at 3- and 6-month follow-up of 0.07. The results obtained suggest that the SSTPQ is a feasible, valid, and reliable tool for the assessment of treatment satisfaction in patients with moderate-to-severe psoriasis.
  Actas Dermo-Sifiliográficas 01/2011; 102(1):28-38.
• Article: [Patch testing increases the likelihood of recognizing lamotrigine as a cause of drug-induced rash].

  L Fuertes, I García-Cano, J Ortiz de Frutos, F Vanaclocha
  Actas Dermo-Sifiliográficas 01/2011; 102(1):64-6.
• Article: [Flat papules on the lip of a young adult].

  I De La Hera, D Cullen, R Rivera, F Vanaclocha
  Actas Dermo-Sifiliográficas 11/2010; 101(9):799-800.
• Article: [Nonalcoholic fatty liver disease and psoriasis].

  R Rivera, F Vanaclocha
  Actas Dermo-Sifiliográficas 10/2010; 101(8):657-8.
• Article: [Multiple cutaneous granular cell tumors].

  B García-Bracamonte, L Fuertes, R Llamas, F Vanaclocha
  Actas Dermo-Sifiliográficas 10/2010; 101(8):732-4.
• Article: [Guidelines on the use of methotrexate in psoriasis].

  G Carretero, L Puig, L Dehesa, J M Carrascosa, M Ribera, M Sánchez-Regaña, E Daudén, D Vidal, M Alsina, C Muñoz-Santos, J L López-Estebaranz, J Notario, C Ferrandiz, F Vanaclocha, M García-Bustinduy, R Taberner, I Belinchón, J Sánchez-Carazo, J C Moreno
  [show abstract] [hide abstract]
  ABSTRACT: Psoriasis, a chronic multifactorial inflammatory disease that develops in genetically predisposed individuals, affects approximately 1.5% of the Spanish population. This disease has a negative impact on patients' quality of life, and long-term therapy is often required to control the symptoms. In addition to the classical systemic treatments (methotrexate, acitretin, cyclosporine, and ultraviolet light), the group of drugs known as biologics (etanercept, infliximab, adalimumab, and ustekinumab) provides the dermatologist with an expanded therapeutic armamentarium, thereby improving the likelihood of controlling psoriasis in patients with severe and/or extensive disease. Methotrexate, a classic antipsoriatic drug, is still very useful either as single-drug therapy or in combination with other systemic drugs, particularly as a rescue therapy or combined with biologics. This article aims to establish the role of methotrexate in the treatment of psoriasis. We considered it of interest to develop guidelines for using methotrexate in the management of psoriasis with a view to ensuring the safe and proper use of this drug in the management of psoriasis. This document was developed by consensus among members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
  Actas Dermo-Sifiliográficas 09/2010; 101(7):600-13.
• Article: [Episodes of flushing and blistering].

  L Fuertes, C Zarco, F Vanaclocha
  Actas Dermo-Sifiliográficas 09/2010; 101(7):643-4.
• Article: [Blepharoconjunctivitis due to phenylephrine].

  V Monsálvez, L Fuertes, I García-Cano, F Vanaclocha, J Ortiz de Frutos
  Actas Dermo-Sifiliográficas 06/2010; 101(5):466-7.
• Article: [Urticaria and mastocytosis: As common as we think?].

  V Monsálvez, I García-Cano, L Fuente, J Ortiz de Frutos, F Vanaclocha
  Actas Dermo-Sifiliográficas 05/2010; 101(4):361-2.
• Article: [Cutaneous lupus erythematosus and vitiligo].

  V Monsálvez, I García-Cano, L Fuertes, R Llamas, F Vanaclocha
  Actas Dermo-Sifiliográficas 05/2010; 101(4):375-7.
• Article: [Comment about patients with dual antiplatelet therapy].

  B García-Bracamonte, F Vanaclocha
  Actas Dermo-Sifiliográficas 03/2010; 101(2):194-5.